ACCESS DB # 1 1 14 1 1

FOR OFFICIAL USE ONLY *PLEASE PRINT CLEARLY*

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: MARK BERCH Examiner #: 59193 Date: 1/24/06

Art Unit: 1624 Phone Number: 2- 0663 Serial Number: 10791910

Location (Bldg/Room#): 5C01 (Mailbox #): 5C18 Results Format Preferred (circle): (PAPER) DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: _____	____ NA Sequence (#)	382.23 STN ____ Dialog
Searcher Phone #: _____	____ AA Sequence (#)	____ Questel/Orbit ____ Lexis/Nexis
Searcher Location: _____	1 Structure (#)	____ Westlaw ____ WWW/Internet
Date Searcher Picked Up: 2/3/06	____ Bibliographic	____ In-house sequence systems
Date Completed: 2/3/06	____ Litigation	____ Commercial ____ Oligomer ____ Score/Length
Searcher Prep & Review Time: 60	____ Fulltext	____ Interference ____ SPDI ____ Encode/Transl
Online Time: 50	____ Other	____ Other (specify)

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 14:23:13 ON 03 FEB 2006

=> d his

     FILE 'HCAPLUS' ENTERED AT 13:43:49 ON 03 FEB 2006
L1            1 S US20040198700/PN
                SEL RN

     FILE 'REGISTRY' ENTERED AT 13:44:11 ON 03 FEB 2006
L2           21 S E1-E21

     FILE 'LREGISTRY' ENTERED AT 13:51:36 ON 03 FEB 2006
L3              STR

     FILE 'REGISTRY' ENTERED AT 13:59:57 ON 03 FEB 2006
L4            0 S L3
L5           22 S L3 FUL
L6           13 S L5 AND L2
                SAV L5 BER910/A

     FILE 'HCAPLUS' ENTERED AT 14:22:49 ON 03 FEB 2006
L7            3 S L5



=> d que l7
L3              STR
```




```
REP G1=(0-20) C
VAR G2=11/14
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS PCY  UNS  AT  14
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M4-X5 C  M1-X2 N  AT  11
ECOUNT  IS E6 C  AT  12
ECOUNT  IS E10 C  AT  14

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L5           22 SEA FILE=REGISTRY SSS FUL L3
L7            3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L5


=> fil hcap
FILE 'HCAPLUS' ENTERED AT 14:23:24 ON 03 FEB 2006
```

=> d l7 1-3 ibib abs hitstr hitind

L7 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:780695 HCAPLUS
DOCUMENT NUMBER: 141:277408
TITLE: Preparation of azetidinones for use in pharmaceutical compns. for treatment of vascular diseases
INVENTOR(S): Burnett, Duane A.; Clader, John W.; Vaccaro, Wayne
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081002	A1	20040923	WO 2004-US6546	2004 0303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2517571	AA	20040923	CA 2004-2517571	2004 0303
US 2004198700	A1	20041007	US 2004-791910	2004 0303
EP 1601668	A1	20051207	EP 2004-716953	2004 0303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-452809P P 2003 0307
WO 2004-US6546 W 2004 0303

OTHER SOURCE(S): MARPAT 141:277408
GI



II I

AB This invention provides for pharmaceutical formulations and processes for preparing substituted azetidinone compds. of the general form G-L-M [G = azetidinone moiety; L = linking group, such as -O(CH2)3NH- or -OCO(CH2)2NH-; M = pharmaceutically active moiety, such as lovastatin or simvastatin], for use in the treatment of vascular conditions such as atherosclerosis or hypercholesterolemia, and for treating Alzheimer's disease, diabetes, obesity, stroke, demyelination and for lowering plasma levels of sterols, stanols and/or cholesterol and for regulating levels of amyloid β peptides. Thus, azetidinone I was prepared via a multistep synthetic sequence starting from the corresponding phenolic azetidinone II, 3-benzyloxy-1-propanol and lovastatin. The prepared azetidinones were evaluated for hypercholesterolemic activity using Golden Syrian hamster as an in vivo model.

IT **760972-15-4P 760972-16-5P 760972-17-6P**
760972-18-7P 760972-19-8P 760972-20-1P
760972-21-2P 760972-22-3P 760972-23-4P
760972-24-5P 760972-25-6P 760972-26-7P
(claimed compound; preparation of azetidinones for use in pharmaceutical compns. for treatment of vascular diseases)

RN 760972-15-4 HCAPLUS

CN β-Alanine, N-[(3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-2,6-dimethyl-1-naphthalenyl]-3,5-dihydroxy-1-oxoheptyl]-, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 760972-16-5 HCAPLUS
CN β-Alanine, N-[(3R,5R)-7-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-2,6-dimethyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-naphthalenyl]-3,5-dihydroxy-1-oxoheptyl]-, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 760972-17-6 HCAPLUS
CN β-Alanine, N-[(3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3,5-dihydroxy-1-oxoheptyl]-, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 760972-18-7 HCAPLUS
CN β-Alanine, N-[(3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-1-oxo-6-heptenyl]-, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



F

PAGE 1-B



RN 760972-19-8 HCAPLUS
CN β-Alanine, N-[(3R,5R)-7-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-6-hydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-naphthalenyl]-3,5-dihydroxy-1-oxoheptyl]-, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 760972-20-1 HCAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-8-[(3R,5R)-7-[[3-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenoxy]propyl]amino]-3,5-dihydroxy-7-oxoheptyl]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-1-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 760972-21-2 HCAPLUS
CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-8-[(3R,5R)-7-[[3-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenoxy]propyl]amino]-3,5-dihydroxy-7-oxoheptyl]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 760972-22-3 HCAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-8-[(3R,5R)-7-[[2-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl]ethyl]amino]-3,5-dihydroxy-7-oxoheptyl]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-1-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 760972-23-4 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-β,δ-dihydroxy-2,6-dimethyl-, 2-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenoxy]ethyl ester, (βR,δR,1S,2S,6R,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 760972-24-5 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-β,δ-dihydroxy-2,6-dimethyl-, 3-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenoxy]-3-oxopropyl ester, (βR,δR,1S,2S,6R,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 760972-25-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-β,δ-dihydroxy-2,6-dimethyl-, 2-[[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenoxy]dimethylsilyl]ethyl ester, (βR,δR,1S,2S,6R,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 760972-26-7 HCAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-8-[(3R,5R)-7-[[2-[[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenoxy]dimethylsilyl]ethyl]amino]-3,5-dihydroxy-7-oxoheptyl]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-1-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **760972-12-1P**
(preparation of azetidinones for use in pharmaceutical compns. for treatment of vascular diseases)

RN 760972-12-1 HCAPLUS

CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-8-[(3R,5R)-3,5-dihydroxy-7-oxo-7-[[3-[4-[(2S,3R)-4-oxo-1-phenyl-3-(3-phenylpropyl)-2-azetidinyl]phenoxy]propyl]amino]heptyl]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07D403-12
ICS C07D205-08; A61K031-397; A61P003-06
CC 26-5 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 63
IT **760972-15-4P 760972-16-5P 760972-17-6P**
760972-18-7P 760972-19-8P 760972-20-1P
760972-21-2P 760972-22-3P 760972-23-4P
760972-24-5P 760972-25-6P 760972-26-7P
(claimed compound; preparation of azetidinones for use in pharmaceutical compns. for treatment of vascular diseases)
IT **760972-12-1P**
(preparation of azetidinones for use in pharmaceutical compns. for treatment of vascular diseases)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:759822 HCAPLUS
DOCUMENT NUMBER: 141:260450
TITLE: Processes for preparation of substituted azetidinone compounds, formulations containing them and uses thereof
INVENTOR(S): Burnett, Duane A.; Clader, John W.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 30 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004180861	A1	20040916	US 2004-792346	2004 0303
CA 2517572	AA	20040923	CA 2004-2517572	2004 0303
WO 2004081003	A1	20040923	WO 2004-US6428	

2004
0303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1601669 A1 20051207 EP 2004-716913
2004
0303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ,
EE, HU, PL, SK
PRIORITY APPLN. INFO.: US 2003-452725P P
2003
0307

WO 2004-US6428 W
2004
0303

OTHER SOURCE(S): MARPAT 141:260450
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT
*

AB The present invention provides substituted azetidinone compds. I [X1 = Xm; X2 = Cq; X3 = Yn; X4 = Cr; X5 = Zp; X, Y, Z = CH2, CH-alkyl, C(Alkyl)2; Q1, Q2 = H, (C0-30-alkylene)-G, OR6, O2CR6, OCO2R9, O2CNR6R7, L-M; Q3 = 1 - 5 substituents, selected from alkyl, alkenyl, alkynyl, (C0-30-alkylene)-G, (C0-10-alkylene)-OR6, (C0-10-alkylene)-C(:O)R6, (C0-10-alkylene)-CO2R6, (C0-10-alkylene)O2CR6, CH:CHCOR6, CH:CHCO2R6, C.tplbond.CCO2R6, C.tplbond.CC(:O)R6, etc.; Q4 = ; Q5 = ; G = sugar, oligo sugar, amino sugar, amino acid, oligopeptide (2 - 9 residues), trialkylammoniumalkyl, SO3H; L = OC(:O)C6H4C(:O)-4, OCO(:O)(CH2)x1C(:O), (CH2)x2C(:O), O(CH2)x3C(:O), OSiMe2(CH2)x4C(:O), OSiMe2(CH2)x5OC(:O), etc.; M = statin linked through O (atorvastatin, simvastatin); R2, R3 = H, alkyl, aryl; R6, R7, R8 = H, alkyl, aryl, aralkyl; R9 = alkyl, aryl, aralkyl; R1 0 = H, alkyl; q = 0, 1; r = 0,1; m, n, p = 0 - 4 (with the proviso that, at least one of q and r = 1, and the sum of m + n + p + q + r = 1 - 6; with the proviso that when p = 0, r = 1 and the sum of m + q + n = 1 - 5); x1 - x11 = 1 - 10; with the proviso that at least one of Q1 - Q5 = L-M, mono-, di-, tri-, tetrasugar, sugar acid, amino sugar, amino acid, etc.], formulations and processes for preparing the same which can be useful for treating vascular conditions such as atherosclerosis or

hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols in a subject. Thus, azetidinone conjugate II can be prepared from ezetimibe acetate (III) via acylation with glutaric anhydride and esterification with simvastatin (IV).

IT **756821-84-8P 756821-86-0P 756821-90-6P 756821-92-8P 756821-93-9P 756821-94-0P 756821-95-1P 756821-96-2P**
(preparation of substituted azetidinone compds. useful for treating vascular conditions)

RN 756821-84-8 HCAPLUS

CN Pentanedioic acid, 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl (2S,4S,4aR,5S,6S)-2,3,4,4a,5,6-hexahydro-6-methyl-4-[(2S)-2-methyl-1-oxobutoxy]-5-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756821-86-0 HCAPLUS

CN Pentanedioic acid, 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl (2R,4R)-2-[2-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 756821-90-6 HCAPLUS
CN Butanoic acid, 4-[4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenoxy]-, (2R,4R)-2-[2-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 756821-92-8 HCAPLUS
CN Pentanedioic acid, 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl (2S,4R)-2-[2-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-2,6-dimethyl-1-naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 756821-93-9 HCAPLUS
CN Pentanedioic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl 2-[2-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

F

RN 756821-94-0 HCAPLUS
CN Butanoic acid, 4-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenoxy]-, 2-[2-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

O

RN 756821-95-1 HCAPLUS

CN Pentanedioic acid, 4-[3-[3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl 2-[2-[1,2,6,7,8,8a-hexahydro-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)



RN 756821-96-2 HCAPLUS
CN Pentanedioic acid, 4-[3-[3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl 2,3,4,4a,5,6-hexahydro-6-methyl-4-(2-methyl-1-oxobutoxy)-5-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)



IC ICM A61K031-675
ICS A61K031-655; A61K031-397
INCL 514079000; 514151000; 514210020; 540200000

CC 26-6 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 25, 33, 34, 63
IT **756821-84-8P 756821-86-0P 756821-90-6P**
756821-92-8P 756821-93-9P 756821-94-0P
756821-95-1P 756821-96-2P
(preparation of substituted azetidinone compds. useful for treating vascular conditions)

L7 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:759821 HCAPLUS
DOCUMENT NUMBER: 141:254573
TITLE: Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
INVENTOR(S): Burnett, Duane A.; Clader, John W.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 35 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004180860	A1	20040916	US 2004-791979	2004 0303
CA 2517573	AA	20040923	CA 2004-2517573	2004 0303
WO 2004081004	A1	20040923	WO 2004-US6555	2004 0303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1606287	A1	20051221	EP 2004-716968	2004 0303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:		
US 2003-452722P	P	2003 0307
WO 2004-US6555	W	2004

OTHER SOURCE(S): MARPAT 141:254573
GI



I

AB This invention provides for pharmaceutical formulations and processes for preparing substituted azetidinone compds. of the general form G-L-M [G = azetidinone moiety, such as I; L = linking group, such as -OCO(CH2)2NH-; M = pharmaceutically active moiety, such as simvastatin], which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination, lowering plasma levels of sterols, stanols and/or cholesterol and regulating levels of amyloid β peptides or treating Alzheimer's disease. A hypothetical in vivo evaluation of hypercholesterolemic activity using Golden Syrian hamster was presented.

IT **756879-00-2DP**, analogs
(azetidinones for use in pharmaceutical compns. for treatment of vascular diseases)

RN 756879-00-2 HCAPLUS

CN β-Alanine, N-[[(3R,4S,4aR,5S,7R)-5-(2,2-dimethyl-1-oxobutoxy)-3,4,4a,5,6,7-hexahydro-3,7-dimethyl-4-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl]carbonyl]-, 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Et

IC ICM A61K031-675
ICS A61K031-655; A61K031-397
INCL 514079000; 514210020; 540200000; 514151000
CC 1-8 (Pharmacology)
Section cross-reference(s): 26, 63
IT **756879-00-2DP**, analogs
(azetidinones for use in pharmaceutical compns. for treatment of vascular diseases)